Welcome to the third of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions involving digital assets are an increasing focus for pharmaceuticals, medical device and medtech companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
In this third episode, we consider the challenges associated with defining and valuing digital assets. Aligning the target’s and acquiror’s views on valuation is obviously key to getting a deal done. Digital assets present some unique challenges for pharmaceutical companies more used to valuing molecules in traditional licensing or acquisition transactions. What techniques do they need to deploy to overcome this hurdle? Click below to listen. You can add the podcast series to one of several apps, such as Apple Podcasts, by clicking the "+ Follow" link.
To learn more, follow this link to download a copy of the report that accompanies the podcast series.